You are here

melanoma

OncoSec’s defense of weak preliminary Tavo data for PD-1 resistant melanoma can’t stop a rout

OncoSec’s defense of weak preliminary Tavo data for PD-1 resistant melanoma can’t stop a rout

Endpoints

Flag link:

Immunotherapy Drugs Slow Skin Cancer That Has Spread to the Brain

Immunotherapy Drugs Slow Skin Cancer That Has Spread to the Brain

New York Times, NY

clinical trials

Bristol-Myers Squibb

Flag link:

Opdivo Approved in Europe for Additional Use in Melanoma Patients

Opdivo Approved in Europe for Additional Use in Melanoma Patients

CP Wire

Bristol-Myers Squibb

advanced melanoma

Flag link:

Opdivo Approved in Europe for Additional Use in Melanoma Patients

Bristol-Myers Squibb

advanced melanoma

Flag link:

Keytruda Becomes the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma

Keytruda Becomes the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma

CP Wire

Flag link:

Keytruda Becomes the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma

Flag link:

Array wrestles FDA OK for its MEK/BRAF melanoma combo, to hit the pharmacy as Mektovi and Braftovi

Array wrestles FDA OK for its MEK/BRAF melanoma combo, to hit the pharmacy as Mektovi and Braftovi

Endpoints

Array Biopharma

Flag link:

Nektar And Bristol Hurtle Forward With Experimental Cancer Drug

Nektar And Bristol Hurtle Forward With Experimental Cancer Drug

Forbes

Bristol-Myers Squibb

renal cell carcinoma

urothelial cancer

Flag link:

NeoImmuneTech and Roche Collaborate in Clinical Trial of HyLeukin-7 in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers

NeoImmuneTech and Roche Collaborate in Clinical Trial of HyLeukin-7 in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers

CP Wire

Merkel cell carcinoma

cutaneous squamous cell carcinoma

Flag link:

NeoImmuneTech and Roche Collaborate in Clinical Trial of HyLeukin-7 in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers

checkpoint inhibitors

Flag link:

Initial Ph II 2b Results of Elios' Personalized Cancer Vaccine for the Treatment of Melanoma Look Promising

Initial Ph II 2b Results of Elios' Personalized Cancer Vaccine for the Treatment of Melanoma Look Promising

CP Wire

Elios Therapeutics

clinical trials

Flag link:

Keytruda Adjuvant Therapy Study Shows Reduced the Risk of Disease Recurrence or Death by More Than 40 Percent Compared to Placebo in Stage III Melanoma

Keytruda Adjuvant Therapy Study Shows Reduced the Risk of Disease Recurrence or Death by More Than 40 Percent Compared to Placebo in Stage III Melanoma

CP Wire

anti-PD-1 immunotherapy

Flag link:

Keytruda Adjuvant Therapy Study Shows Reduced the Risk of Disease Recurrence or Death by More Than 40 Percent Compared to Placebo in Stage III Melanoma

Flag link:

Wistar Researchers Find Combination Therapy Effective for NRAS Mutant and Therapy Resistant Melanoma

Wistar Researchers Find Combination Therapy Effective for NRAS Mutant and Therapy Resistant Melanoma

CP Wire

Wistar Institute

Flag link:

Wistar Researchers Find Combination Therapy Effective for NRAS Mutant and Therapy Resistant Melanoma

Flag link:

Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment

Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment

Marketwatch

clinical trials

metastatic melanoma

Flag link:

FDA approves new dosing for Bristol-Myers Squibb's Opdivo

FDA approves new dosing for Bristol-Myers Squibb's Opdivo

Yahoo/Reuters

Bristol-Myers Squibb

Flag link:

Merck’s melanoma drug shows early promise for resistant cancers in PhI trial

Merck’s melanoma drug shows early promise for resistant cancers in PhI trial

Endpoints

clinical trials

Flag link:

Array melanoma drugs show significant survival versus Roche drug in study

Array melanoma drugs show significant survival versus Roche drug in study

Reuters

Array Biopharma

Flag link:

Merck's Keytruda nabs new data to rival Bristol-Myers' Opdivo at fending off melanoma's return

Merck's Keytruda nabs new data to rival Bristol-Myers' Opdivo at fending off melanoma's return

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Pages